Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Provided By PR Newswire

Last update: Sep 11, 2024

SAN DIEGO, Sept. 11, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today provided a corporate and REM-001 clinical study update.